Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30
Gilead Sciences (NASDAQ: GILD ) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100 billion-$30.400 billion vs $30.427 billion estimate.
Story updates
08:03:08 PM UTC
SquawkNews
Gilead Sciences (NASDAQ: GILD ) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) analyst estimate..
Gilead Sciences (NASDAQ: GILD ) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate.
Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100 billion-$30.400 billion vs $30.427 billion estimate.